Israel’s Chiasma has developed the oral treatment Octreotide, for acromegaly – abnormal growth due to a tumor of the pituitary gland that causes severe life-threatening health problems. Chiasma is also planning an IPO on NASDAQ.

http://www.chiasmapharma.com/news/chiasma-submits-new-drug-application-us-fda-octreotide-capsules-acromegaly

http://www.globes.co.il/en/article-chiasma-files-for-86m-nasdaq-ipo-1001045453